One Bench at a Time

We Welcome Prellis Biologics

 
Prellis Biologics is developing technology to build transplantable human organs and tissues. Their aim is to address the organ shortage and provide human tissues to streamline the development of therapeutics. The first transplantable human tissues Prellis Biologics is working to develop are the insulin secreting units of the pancreas, Islets of Langerhans. A renewable, safe source of Islets of Langerhans will provide an option to millions of people living with Type 1 Diabetes Mellitus (T1DM). An islet transplant may allow T1DM patients to become insulin independent thereby avoiding daily injections and finger pricks for monitoring and regulating dangerous blood sugar swings. In addition, our company has developed a printing process to create human Lymph Node Organoids (LNO), capable of immune responses and generation of human antibodies, bypassing the need for antibody development in animals. In our proof-of-concept studies, our scientists created 14 novel class-switched human IgG antibodies that are reactive to the Zika Virus in less than 6 weeks. By engineering human tissues in the laboratory for rapid therapeutics development, our technology will streamline bench-to-bedside research and efficiently address emerging disease outbreaks. Prellis Biologics was co-founded in 2016 by Dr. Melanie Matheu and Dr. Noelle Mullin, two Ph.D.’s with a passion for bringing engineering and biology together to solve unmet medical needs.

Upcoming Event

  • Office Hours with WSGR Patent and Corporate Law

    09:00-11:00
    03/01/2018
    To apply for Office Hours contact: Carol Ochoa Sponsored by:
    Ali Alemozafar Dr. Ali R. Alemozafar is a senior associate at Wilson Sonsini Goodrich & Rosati, where he focuses on patent prosecution, strategic patent counseling, and IP due diligence in a wide range of technical fields, including diagnostics, therapeutics, genomics, and materials. Ali received his Ph.D. in chemical engineering at Stanford University, where he investigated the reactivity and atomic-scale changes accompanying reactions on various catalysts. During his postdoctoral research fellowship at the Department of Chemistry and Chemical Biology at Harvard University, he investigated the dynamics of TiOx nanoparticles and the use of gold as an oxidation catalyst. Prior to attending law school, Ali worked on data warehousing, business intelligence, and enterprise data integration. Ali frequently lectures at the UC Berkeley School of Law and UC Hastings College of the Law on various intellectual property topics, including patent strategy and IP due diligence. Michael Hostetler Dr. Mike Hostetler is a partner in the SOMA and San Diego offices of Wilson Sonsini Goodrich & Rosati, where he provides strategic intellectual property counseling to more than 100 growth enterprises in the pharmaceutical and biotechnology, and information technology industries. He works with both venture-backed and public companies. His expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology, and information technology products in all stages of development, from proof of concept to regulatory approval to product launch. He leads a talented team of patent associates and patent agents that can meet virtually any technical and strategic need. Mike currently serves as a member of the firm's Policy and Nominating Committees. Elton Satusky Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter